Literature DB >> 7483123

The epidemiology of erectile dysfunction.

A E Benet1, A Melman.   

Abstract

During the last two decades, significant advances have been made in the understanding of male sexual dysfunction. Concomitantly, a marked increase in both clinical and research activity in the field of male erectile dysfunction has led to a better evaluation and more treatment options. The prevalence and incidence are dependent on the definitions used, the diagnostic tolls, and the treatment options. Using standard definitions as suggested by the NIH Consensus Conference and improving our diagnostic and treatment options will have a major impact on the epidemiology of ED. A summary of the risk factors for ED is presented in Table 3. Still more epidemiologic research is essential to further understand the distribution as well as the prevalence of ED in certain ethnic groups, chronic conditions, and as a result of surgery and trauma. These studies will help us improve our diagnostic skills as well as our therapeutic options.

Entities:  

Mesh:

Year:  1995        PMID: 7483123

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  36 in total

1.  Erectile function in two-kidney, one-clip hypertensive rats is maintained by a potential increase in nitric oxide production.

Authors:  A Elizabeth Linder; Anne M Dorrance; Thomas M Mills; R Clinton Webb; Romulo Leite
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

2.  Viagra: a botched test case for rationing.

Authors:  J Chisholm
Journal:  BMJ       Date:  1999-01-30

3.  Correlation between peak systolic velocity and diameter of cavernosal arteries in flaccid versus dynamic state for the evaluation of erectile dysfunction.

Authors:  R Souper; J Hartmann; M Alvarez; I Fuentes; G Astroza; M Marconi
Journal:  Int J Impot Res       Date:  2017-04-06       Impact factor: 2.896

Review 4.  Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members.

Authors:  H L Tan
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

5.  Assessing sexual functioning in patients with chronic disorders by using a generic health-related quality of life questionnaire.

Authors:  P E Wändell; B Brorsson
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

6.  Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men.

Authors:  Arie Roth; Ofra Kalter-Leibovici; Yehuda Kerbis; Ella Tenenbaum-Koren; Juza Chen; Tamar Sobol; Itamar Raz
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

7.  Prevalence and determinants of erectile dysfunction in patients on peritoneal dialysis.

Authors:  Rajesh Krishnan; Sharon Izatt; Joanne M Bargman; Dimitrios Oreopoulos
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

8.  Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.

Authors:  M T Rosenberg; P L Adams; T A McBride; J N Roberts; S W McCallum
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

9.  A multicenter, randomized, open-labeled, parallel group trial of sildenafil in alcohol-associated erectile dysfunction: the impact on psychosocial outcomes.

Authors:  Alexander M Ponizovsky; Lev Averbuch; Ira Radomislensky; Alexander Grinshpoon
Journal:  Int J Environ Res Public Health       Date:  2009-09-23       Impact factor: 3.390

Review 10.  Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?

Authors:  Yoram Vardi
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.